Navigation Links
Trovagene to Present at Two Healthcare Conferences

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ:  TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. is scheduled to present a corporate overview at the following 2013 healthcare conferences: Rodman & Renshaw and Stifel.


Rodman & Renshaw 15th Annual Global Healthcare ConferenceTrovagene is scheduled to present at the 15th Annual Rodman & Renshaw Global Healthcare Conference at the Millennium Broadway Hotel in New York, NY on Monday, September 9, 2013 at 3:15 p.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at and can also be accessed through the investor relations page at A replay of the presentation will be available at and will be archived for 90 days.

Stifel Healthcare Conference 2013Trovagene is scheduled to present at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA on Wednesday, September 11, 2013 at 10:20 a.m. Mr. Schuh will be available for one-on-one meetings during the conference. The presentation will be webcast live at and can also be accessed through the investor relations page at A replay of the presentation will be available at and will be archived for 90 days.

About Trovagene, Inc.Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.ContactTrovagene, Inc.FinancialInvestor RelationsStephen Zaniboni

Chief Financial OfficerAmy Caterina

Investor RelationsTrovagene, Inc.Trovagene,

SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Trovagene to Present at Leerink Swan Global Healthcare Conference
2. Trovagene to be Added to Russell Microcap Index
3. Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.
4. Trovagene and Strand Life Sciences Plan Collaboration to Validate and Offer Urine-Based HPV Screening Test in India and South Asia
5. TrovaGene Acquires CLIA - Certified Laboratory
6. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
7. Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
8. Synthetic Biologics to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City
9. ANP to present at and attend major US investment, partnering and industry conferences
10. Cambridge Semantics to Present on ‘Smart Data’ During Deep-Dive Workshop at 2013 Big Data Innovation Summit
11. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November 30, ... (ECNR) in Vienna, Austria to ... Congress of NeuroRehabilitation (ECNR) in Vienna, Austria ... NovaVision, a wholly owned subsidiary of Vycor Medical, Inc. ... of its Internet-delivered NovaVision Therapy Suite at the 3rd ...
(Date:11/28/2015)... ... 2015 , ... • Jeon Jin Bio Corp, a Korean Biotech venture company, ... , Bird Free, an oil-based, gel formula made ... including visual, smell, taste and touch, enabling safe, effective avian control without toxic chemicals ...
(Date:11/26/2015)... 2015 ... Research Laboratories, a leading independent and ... has formed a strategic partnership with ... Health for joint work on clinical ... ) , --> ,     ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):